Arimoclomol

Arimoclomol (BRX-220 free base) is an orally active co-inducer of heat shock proteins (HSP) [1]. Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system[2].Arimoclomol can be used for the study of Niemann–Pick disease type C.

Product Specifications

CAS Number

289893-25-0

Product Name Alternative

BRX-220 (free base)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/arimoclomol.html

Purity

99.83

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

Cl/C(C1=C[N+]([O-])=CC=C1)=N\OC[C@H](O)CN2CCCCC2

Molecular Formula

C14H20ClN3O3

Molecular Weight

313.78

Precautions

H302, H315, H319, H335

References & Citations

[1]Rakonczay Z Jr, et al. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med. 2002 Jun 15;32 (12) :1283-92.|[2]Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13 (7) :482-96.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

HSP

Citation 01

Res Sq. 2025 Mar 31.|University of Tubingen. 2025.|Exp Eye Res. 2019 Nov;188:107792.|Iran J Med Sci. 2024 May 16.|University of Graz. Institute of Pharmaceutical Science. 2021 Nov.